Institutions / Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P.
CIK 1892134 · Institution · as of Dec 31, 2025
Portfolio value
$3.72B
Positions
40
As of
Dec 31, 2025
Top holdings
Dec 31, 2025View all 40 →
| Company | Value | % of portfolio |
|---|---|---|
| Newamsterdam Pharma Company | $594.39M | 16.0% |
| Mirum Pharmaceuticals, Inc. | $536.75M | 14.4% |
| Arcutis Biotherapeutics, Inc. | $286.76M | 7.7% |
| BridgeBio Pharma, Inc. | $271.20M | 7.3% |
| MBX Biosciences, Inc.MBX | $209.80M | 5.6% |
| Phathom Pharmaceuticals, Inc.PHAT | $206.82M | 5.6% |
| Maze Therapeutics, Inc. | $189.22M | 5.1% |
| Trevi Therapeutics, Inc. | $128.45M | 3.4% |
| Krystal Biotech, Inc. | $120.42M | 3.2% |
| Disc Medicine, Inc.IRON | $100.06M | 2.7% |
| Erasca, Inc.ERAS | $84.55M | 2.3% |
| KalVista Pharmaceuticals Inc | $81.39M | 2.2% |
| Palvella Therapeutics, Inc.PVLA | $75.61M | 2.0% |
| Avidity Biosciences, Inc. | $70.91M | 1.9% |
| Revolution Medicines, Inc. | $63.52M | 1.7% |
| Dyne Therapeutics, Inc. | $61.67M | 1.7% |
| Tarsus Pharmaceuticals, Inc. | $59.66M | 1.6% |
| Savara IncSVRA | $59.47M | 1.6% |
| Cytokinetics Inc | $59.39M | 1.6% |
| Abivax SA | $51.02M | 1.4% |
| Lexeo Therapeutics, Inc. | $43.94M | 1.2% |
| Agios Pharmaceuticals, Inc. | $34.83M | 0.9% |
| ACADIA Pharmaceuticals Inc | $34.65M | 0.9% |
| Zai Lab Limited | $33.56M | 0.9% |
| Rapt Therapeutics Inc | $33.31M | 0.9% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.